These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 32997517)

  • 1. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
    Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
    AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis.
    Jun BG; Kim SG; Kim YD; Cheon GJ; Han KH; Yoo JJ; Kim YS; Jeong SW; Jang JY; Lee SH; Park S; Kim HS
    PLoS One; 2018; 13(10):e0206381. PubMed ID: 30379885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis.
    Wong TC; Chiang CL; Lee AS; Lee VH; Yeung CS; Ho CH; Cheung TT; Ng KK; Chok SH; Chan AC; Dai WC; Wong FC; Luk MY; Leung TW; Lo CM
    Surg Oncol; 2019 Mar; 28():228-235. PubMed ID: 30851906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma.
    Shen PC; Chang WC; Lo CH; Yang JF; Lee MS; Dai YH; Lin CS; Fan CY; Huang WY
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):307-318. PubMed ID: 31175903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Long-Term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial Chemoembolization: A propensity score matched study.
    Zhang K; Mu L; Ren Y; Jiang T
    Eur J Radiol; 2023 Oct; 167():111092. PubMed ID: 37708678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center.
    Chen QF; Jia ZY; Yang ZQ; Fan WL; Shi HB
    Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1748-1755. PubMed ID: 28681222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma.
    Chiang CL; Chan MKH; Yeung CSY; Ho CHM; Lee FAS; Lee VWY; Wong FCS; Blanck O
    Strahlenther Onkol; 2019 Mar; 195(3):254-264. PubMed ID: 30413833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between Trans-Arterial Chemoembolization Followed by Stereotactic Body Radiation Therapy and Trans-Arterial Chemoembolization Alone in BCLC Stage B Hepatocellular Carcinoma: A Pilot Study.
    Saad E; Abdulla M; Nassef A; Ebrahim N; Abdel Moneim R
    Asian Pac J Cancer Prev; 2024 Sep; 25(9):3073-3079. PubMed ID: 39342585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360).
    Comito T; Loi M; Franzese C; Clerici E; Franceschini D; Badalamenti M; Teriaca MA; Rimassa L; Pedicini V; Poretti D; Solbiati LA; Torzilli G; Ceriani R; Lleo A; Aghemo A; Santoro A; Scorsetti M
    Curr Oncol; 2022 Nov; 29(11):8802-8813. PubMed ID: 36421345
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
    English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
    JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
    Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
    Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
    Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical resection versus transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma.
    Allignet B; Pradat P; Mornex F; Izarn F; Rode A; Mabrut JY; Mohkam K; Merle P
    Strahlenther Onkol; 2023 Mar; 199(3):293-303. PubMed ID: 36441171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
    Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
    J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.